Both in Pharmaceuticals
Neurogene vs Bicara Therapeutics
Over the past year NGNE returned −14.3% and BCAX returned −50.4%; their daily moves had a correlation of 0.11.
NGNE −14.3% BCAX −50.4%Growth of $1, one year, split-adjusted
| Metric | NGNE | BCAX |
|---|---|---|
| Price | $26.61 | $7.93 |
| Market cap | $532.5M | $524.8M |
| Today | −3.41% | −13.14% |
| 1 month | +3.7% | −55.0% |
| 6 months | −5.7% | −65.1% |
| Year to date | +29.2% | −52.9% |
| 1 year | −19.7% | −51.8% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $225.4M | $497.3M |
| Dividend yield | — | — |
| Volatility (60d) | 76.5% | 131.6% |
| Short % of float | 39.6% | 23.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).